Novel primary malignancies, tumor promotion in BRAF wild-type patients, hemorrhage, venous thromboembolism, cardiomyopathy, ocular toxicities, febrile reactions, skin toxicity, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency94–96. This evidence concerns the gene BRAF and neoplasm.